Book An Appointment
Arabic
Arabic

Brugada Syndrome treatment in Dubai

Services

Conditions Treated

Some heart conditions are hidden in your genes, silent but potentially life-threatening.

Electrical abnormalities from genetic syndromes can pose serious risks without structural signs. Early detection and expert care are essential for genetic and rare cardiac syndromes.

Dr. Muhamed Shaloob, renowned Interventional Cardiologist at JTS Medical Centre, Dubai, offers comprehensive evaluation and advanced treatment for Genetic and Rare Cardiac Syndromes.

Genetic & Rare Cardiac Syndromes

A. Brugada Syndrome

Brugada Syndrome is a rare genetic heart rhythm disorder that disrupts the heart’s electrical system, increasing the risk of dangerous arrhythmias and sudden cardiac events. For those seeking Brugada Syndrome treatment in Dubai, Dr. Muhamed Shaloob, an expert cardiologist specializing in inherited arrhythmias, offers advanced diagnosis, ECG evaluation, and personalized management.

Patients remain undiagnosed until a Brugada ECG pattern is found during regular screenings or after an unexpected cardiac event.

Classical features of Brugada Syndrome:

  • Brugada Syndrome ECG presents a typical “coved-type” ST-segment elevation in the right precordial leads (V1–V3). The Brugada syndrome ECG pattern must be evaluated closely to confirm a diagnosis.
  • This Brugada ECG pattern can be classified into Brugada pattern types 1, 2, or 3.
  • Brugada arrhythmia can occur without any structural defect.
  • The common Brugada symptom includes fainting or sudden collapse, especially during rest.
  • Sudden cardiac death is common.

Brugada Syndrome Treatment in Dubai

Brugada disease is a genetic condition that can lead to dangerous heart rhythms.

Evaluation and treatment include;

  • Evaluation and treatment include;
  • Brugada genetic testing helps confirm the diagnosis in patients and family members
  • Electrophysiological studies
  • ICD (Implantable Cardioverter-Defibrillator) placement for high-risk cases

Monitoring Brugada syndrome heart rate is essential, especially in patients with recurrent arrhythmias.
Timely detection and management of Brugada heart syndrome can significantly reduce the risk of untimely cardiac death.

Certain medications and triggers need to be avoided.

Brugada Syndrome treatment in dubai - المتلازمات القلبية الوراثية والنادرة

B. Long QT Syndrome

Long QT Syndrome (LQTS) is a genetic disorder affecting the cardiac electrical activity, leading to prolonged QT intervals on ECG. This also has a predisposition to arrhythmias.

Common Symptoms:

  • Fainting (especially during exercise or stress)
  • Irregular heartbeat
  • Seizure-like episodes

Important things to note:

  • Things to avoid with long QT syndrome include strenuous activity, certain medications, and electrolyte imbalances.
  • The long QT syndrome death rate is higher in untreated cases with recurrent syncope or arrhythmias.
  • The long QT syndrome ECG shows prolonged QT intervals, increasing the chance of arrhythmias.

Long QT Syndrome Treatment in Dubai

Advanced care for long QT syndrome in Dubai focuses on risk reduction and symptom control.

For this genetic ailment, the following parameters need to be evaluated and monitored.

  • Detailed ECG interpretation
  • Family screening
  • Beta-blocker therapy
  • ICD implantation for high-risk cases
  • Lifestyle modifications

C. ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy)

ARVC is a genetic heart disease that affects the right ventricle, causing the heart muscle to be replaced by fibrous or fatty tissue. ARVC heart disease may lead to life-threatening ventricular arrhythmias and sudden cardiac death.

What Is ARVC?

  • ARVC is diagnosed using imaging, ECG, genetic testing, and family history
  • Symptoms include palpitations, fainting, and arrhythmias

ARVC Treatment in Dubai

Patients with a family history should consider evaluation at a specialized ARVC cardiology center.

  • Risk stratification for young athletes and concerned family members
  • ARVC genetic testing
  • ICD implantation and lifestyle counseling
  • Monitoring for heart failure progression
Brugada disease, Brugada syndrome ECG

D. Non-Compaction Cardiomyopathy

This cardiomyopathy is characterized by an abnormal and spongy appearance of the cardiac muscles and reduced pumping efficiency.

Symptoms:

  • Fatigue, along with shortness of breath
  • Irregular heartbeats
  • Risk of stroke and heart failure

Treatment options

  • Treatment focuses on the management of heart failure, arrhythmia prevention, and reducing the risk of thromboembolism.
  • It includes medications like beta-blockers, ACE inhibitors, and anticoagulants, as well as, depending on the severity, the implantation of devices such as an ICD.

Meet Your Specialist: Dr. Muhamed Shaloob

With over 12 years of clinical experience, Dr. Muhamed Shaloob combines his in-depth knowledge of electrophysiology, genetics, and cardiomyopathies for personalized care using the latest diagnostic tools and treatment methodologies.

He also offers advanced diagnostics & genetic testing:

  • Brugada syndrome genetic testing
  • ARVC panel testing
  • Family cascade screening
  • Electrophysiological studies
  • 24-hour Holter & loop recorders

With a focus on early diagnosis and family screening, Dr. Shaloob helps you take proactive steps to protect your heart health.

Take Control of Your Heart Health

If you or a family member has a history of unexplained fainting, abnormal ECGs, or sudden cardiac events, don’t delay. Get a precise diagnosis and expert guidance from Dr. Muhamed Shaloob, one of the leading cardiologists in Dubai, specializing in rare and genetic cardiac syndromes.

Book an appointment now

FAQ’S

Fever, certain medications, alcohol, and electrolyte imbalances can unmask or worsen the Brugada ECG pattern.

Drugs like certain antiarrhythmics, antidepressants, and anesthetics may trigger arrhythmias in Brugada patients.

Yes, it can cause sudden cardiac death, especially in untreated symptomatic individuals.

Spanish cardiologists Pedro and Josep Brugada first described the syndrome in 1992.

It affects approximately 1 in 2,000 people and is more common in Southeast Asia.

Genetic mutations affecting cardiac sodium channels, mainly the SCN5A gene.

It was first clinically recognized in 1992.

Diagnosis is based on ECG findings, sometimes requiring a drug challenge or electrophysiological study.

Estimates suggest tens of thousands globally, though many remain undiagnosed.

Exact global numbers are unknown; risk depends on symptoms and ECG features.

It is classified as a rare cardiac disorder with variable penetrance and presentation.

It is a genetic heart rhythm disorder that increases the risk of sudden cardiac arrest due to faulty electrical signals.

Book An Appointment